Roche to acquire Promedior and with it PRM 151 a proposed treatmemt for fibrotic diseases

Promedior, Inc.,announced that it has entered into a definitive merger agreement for Roche to acquire Promedior. With this acquisition, Roche will obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, notably PRM 151. Promedior, a privately held clinical-stage biotechnology company based in Lexington, Massachusetts, has successfully advanced PRM 151 in human clinical trials and received Breakthrough Therapy Designation from the FDA earlier this year for idiopathic pulmonary fibrosis (IPF). PRM 151, a recombinant form of human pentraxin-2 (PTX-2) protein, has demonstrated both prevention and reversal of fibrosis and opens up new opportunities to treat a wide range of systemic fibrotic diseases. Phase II trial results demonstrated that PRM 151 is the first molecule to show significant lung function improvements on top of current therapies in IPF. PRM 151 has also shown promising early clinical trial data in myelofibrosis (MF) and its anti-fibrotic mechanism has therapeutic potential in other fibrotic diseases.